Cogent Biosciences COGT
NASDAQ COGT
$29.81 -1.83 (-5.78%)
As of: Nov 11, 2026 · 11:46 AM EST

Cogent Biosciences (COGT) EBITDA Margin (2017 - 2020)

Updated

Cogent Biosciences' EBITDA Margin was -1035.18% in FY2020, down 897.91 percentage points from -137.27% in FY2019.

Analysis

Cogent Biosciences (COGT) EBITDA Margin (2017 - 2020) Analysis & Trends

From FY2017 onward, Cogent Biosciences has reported EBITDA Margin for 4 years.

  • EBITDA Margin shows a three-year change of -736.36 percentage points (FY2017 to FY2020).
  • Per Business Quant data, EBITDA Margin in earlier years was -137.27% in FY2019 (+219.05 pp), -356.32% in FY2018 (-57.50 pp) and -298.82% in FY2017.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBITDA Margin (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn 36.69%
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn 32.68%
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn 46.88%
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn 40.60%
5 Novartis Ag 311.58 Bn 285.16 Bn - -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn 39.77%
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn 46.62%
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn 50.63%
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn 42.49%
10 Cogent Biosciences 5.50 Bn 2.15 Bn - -
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2020 -18,293.91%
Jun 30, 2020 -1,347.92%
Mar 31, 2020 -83.15%
Dec 31, 2019 16.71%
Sep 30, 2019 -1,148.82%
Jun 30, 2019 -325.37%
Mar 31, 2019 -377.04%
Dec 31, 2018 -227.39%
Sep 30, 2018 -501.52%
Jun 30, 2018 -547.06%
Mar 31, 2018 -300.36%
Dec 31, 2017 -309.61%
Sep 30, 2017 -294.72%
Jun 30, 2017 -276.43%
Mar 31, 2017 -316.86%
API Access

Cogent Biosciences EBITDA Margin API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=ebitda-margin&ticker=COGT&period=max&api_key=YOUR_API_KEY